Chiasma Inc. (NASDAQ:CHMA) shot up 2.3% during trading on Monday . The company traded as high as $2.80 and last traded at $2.71, with a volume of 53,733 shares. The stock had previously closed at $2.65.

A number of equities research analysts recently issued reports on CHMA shares. Zacks Investment Research downgraded shares of Chiasma from a “hold” rating to a “sell” rating in a report on Monday, April 25th. Cowen and Company restated a “hold” rating on shares of Chiasma in a report on Friday, May 13th. William Blair downgraded shares of Chiasma from an “outperform” rating to a “market perform” rating in a report on Monday, April 18th. Barclays PLC downgraded shares of Chiasma from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $40.00 to $5.50 in a report on Monday, April 25th. Finally, Oppenheimer Holdings Inc. restated an “outperform” rating and issued a $9.00 target price (down from $43.00) on shares of Chiasma in a report on Monday, April 18th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company’s stock. Chiasma currently has an average rating of “Hold” and an average price target of $19.70.

The firm’s 50-day moving average price is $2.76 and its 200 day moving average price is $6.27. The firm’s market cap is $65.61 million.

Chiasma (NASDAQ:CHMA) last released its earnings results on Wednesday, May 11th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.08. Equities analysts predict that Chiasma Inc. will post ($2.66) EPS for the current year.

Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.